Drug–drug interactions with statins: will pitavastatin overcome the statins’ Achilles’ heel?

References

• Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81
   PubMed Web of Science ®Google Scholar
• Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009;373:929-40
   PubMed Web of Science ®Google Scholar
• Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97:52-60C
   PubMed Web of Science ®Google Scholar
• Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006;97:27-31C
   PubMed Web of Science ®Google Scholar
• Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90
   PubMed Web of Science ®Google Scholar
• Schuler J, Duckelmann C, Beindl W, et al. Polypharmacy and inappropriate prescribing in elderly internal-medicine patients in Austria. Wien Klin Wochenschr 2008;120:733-41
   PubMed Web of Science ®Google Scholar
• McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002;36:1331-6
   PubMed Web of Science ®Google Scholar
• Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5
   PubMed Web of Science ®Google Scholar
• Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother 2007;5:345-51
   PubMedGoogle Scholar
• Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 2004;329:15-19
   PubMed Web of Science ®Google Scholar
• Linton A, Garber M, Fagan NK, et al. Examination of multiple medication use among TRICARE beneficiaries aged 65 years and older. J Manag Care Pharm 2007;13:155-62
   PubMed Web of Science ®Google Scholar
• Kinirons MT, Crome P. Clinical pharmacokinetic considerations in the elderly. An update. Clin Pharmacokinet 1997;33:302-12
   PubMed Web of Science ®Google Scholar
• Mayerssohm MB. Special considerations in the elderly. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, 3rd edn. Vancouver: Lippincott Williams & Wilkins, 1994: Ch. 9
   Google Scholar
• Egger SS, Ratz Bravo AE, Hess L, et al. Age-related differences in the prevalence of potential drug–drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging 2007;24:429-40
   PubMed Web of Science ®Google Scholar
• Ratz Bravo AE, Tchambaz L, Krahenbuhl-Melcher A, et al. Prevalence of potentially severe drug–drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf 2005;28:263-75. Erratum in: Drug Saf 2007;30:726
   PubMed Web of Science ®Google Scholar
• Ming EE, Davidson MH, Gandhi SK, et al. Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases. J Clin Lipidol 2008;2:453-63
   PubMed Web of Science ®Google Scholar
• Stang P, Morris L, Kempf J, et al. The coprescription of contraindicated drugs with statins: continuing potential for increased risk of adverse events. Am J Ther 2007;14:30-40
   PubMedGoogle Scholar
• Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006;112:71-105
   PubMed Web of Science ®Google Scholar
• Corsini A, Bellosta S. Drug–drug interaction with statins. Expert Rev Clin Pharmacol 2008;1:105-13
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565-81
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin-associated adverse effects and drug–drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs 2010;10:11-28
   PubMed Web of Science ®Google Scholar
• Fujino H, Yamada I, Shimada S, et al. Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans. Arzneimittelforschung 2002;52:745-53
   PubMed Web of Science ®Google Scholar
• Fujino H, Saito T, Tsunenari Y, et al. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica 2004;34:961-71
   PubMed Web of Science ®Google Scholar
• Ose L. Pitavastatin: a distinctive lipid-lowering drug. Clin Lipidol 2010;5:309-23
   Web of Science ®Google Scholar
• Suzuki M, Iwasaki H, Fujikawa Y, et al. Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors. Bioorg Med Chem 2001;9:2727-43
   PubMed Web of Science ®Google Scholar
• Fujino H, Yamada I, Shimada S, et al. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica 2003;33:27-41
   PubMed Web of Science ®Google Scholar
• Ieiri I, Higuchi S, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 2009;5:703-29
   PubMed Web of Science ®Google Scholar
• Boyd RA, Stern RH, Stewart BH, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 2000;40:91-8
   PubMed Web of Science ®Google Scholar
• Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005;44:1227-46
   PubMed Web of Science ®Google Scholar
• Einarson TR, Metge CJ, Iskedjian M, et al. An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme A reductase inhibitors on health care utilization: a Canadian population-based study. Clin Ther 2002;24:2126-36
   PubMed Web of Science ®Google Scholar
• Fichtenbaum CJ, Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 2002;41:1195-211
   PubMed Web of Science ®Google Scholar
• Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. Aids 2002;16:569-77
   PubMed Web of Science ®Google Scholar
• Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract 2005;17:123-32
   PubMedGoogle Scholar
• Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N Engl J Med 2008;359:789-99
   PubMed Web of Science ®Google Scholar
• Romaine SP, Bailey KM, Hall AS, et al. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J 2010;10:1-11
   PubMed Web of Science ®Google Scholar
• Bailey KM, Romaine SP, Jackson BM, et al. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. Circ Cardiovasc Genet 2010;3:276-85
   PubMed Web of Science ®Google Scholar
• Ieiri I, Suwannakul S, Maeda K, et al. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 2007;82:541-7
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (Clinical guidelines CG67) 2008 [cited 2010 6 October]; Available from: http://guidance.nice.org.uk/cg67
   Google Scholar
• Hirano M, Maeda K, Shitara Y, et al. Drug–drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 2006;34:1229-36
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Investig Drugs 2010;11:323-32
   PubMed Web of Science ®Google Scholar
• Budinski D, Arneson V, Hounslow N, et al. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol 2009;4:291-302
   Web of Science ®Google Scholar
• Ose L, Budinski D, Hounslow N, et al. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin 2009;25:2755-64
   PubMed Web of Science ®Google Scholar
• Stender S, Hounslow N. Robust efficacy of pitavastatin and comparable safety to pravastatin. Atherosclerosis Suppl 2009;10:P770
   Web of Science ®Google Scholar
• Teramoto T, Shimano H, Yokote K, et al. New evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opin Pharmacother 2010;11:817-28
   PubMed Web of Science ®Google Scholar
• Hiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009;54:293-302
   PubMed Web of Science ®Google Scholar
• Kurihara Y, Douzono T, Kawakita K, et al. A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (LIVALO® tablet): LIVALO effectiveness and safety (LIVES) study. Jpn Pharmacol Ther 2008;36:709-31
   Google Scholar
• Saito Y. Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vasc Health Risk Manag 2009;5:921-36
   PubMedGoogle Scholar
• FDA. Guidance for Industry: drug interaction studies – study design, data analysis, and implications for dosing and labeling. Draft guidance September 2006: Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf
   Google Scholar
• Teramoto T, Saito Y, Yamada N, et al. Clinical safety and efficacy of NK-104 (pitavastatin), a new synthetic HMG-CoA reductase inhibitor, in the long-term treatment of hyperlipidemia – results of a multicenter long-term study. J Clin Therap Med 2001;17:885-913
   Google Scholar